Figure 6From: Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivationBiochemical effects of HSP90 inhibitor AUY922 in ovarian cancer cell lines. A) EGFR, ERBB2, MET, AXL, AKT, MAPK and S6 are inhibited, after 4 h AUY922 treatment in serum-free medium. β-actin stain is a loading control. B) Inhibition of EGFR, Erbb2, MET, AXL and AKT expression, with concomitant upregulation of p27, and variable Caspase 8 and PARP cleavage, after 48 h AUY922 treatment in serum-containing medium. β-actin stain is a loading control. C) Ovarian cancer cell viability was determined by the CellTiter-Glo assay after 72 h treatment with HSP90 inhibitor, AUY922. The data were normalized to the DMSO control, and represent the mean values (± s.d.) of quadruplicate cultures (*p < 0.05, **P < 0.01, n = 3). D) Apoptosis was evaluated in ovarian cancer cell lines, at 72 h after treatment with AUY922. Caspase 3/7 activity was measured using a Caspase-Glo luminescence assay. The data were normalized to the DMSO control, and represent the mean values (± s.d.) from quadruplicate cultures (*p < 0.05, **P < 0.01, n = 3). E) Apoptosis analyses following AUY922 (0.5 and 1 μM) treatment for 48 hours by using PE Annexin V Apoptosis Detection Kit I. F) Cell cycle analyses after 48 hours inhibitor treatment in serum-containing medium.Back to article page